Literature DB >> 21472500

Drug vs class-specific black box warnings: does one bad drug spoil the bunch?

Stacie B Dusetzina, G Caleb Alexander.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21472500      PMCID： PMC3101978          DOI： 10.1007/s11606-011-1714-9

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  14 in total

Review 1.  The public health implications of the 1995 'pill scare'.

Authors:  A Furedi
Journal:  Hum Reprod Update       Date:  1999 Nov-Dec       Impact factor: 15.610

2.  Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2002-01-22       Impact factor: 8.262

Review 3.  Communication of medical product risk: how effective is effective enough?

Authors:  Stephen A Goldman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Insiders criticise FDA's decision not to withdraw rosiglitazone.

Authors:  Deborah Cohen
Journal:  BMJ       Date:  2010-09-28

5.  Different black box warning labeling for same-class drugs.

Authors:  Orestis A Panagiotou; Despina G Contopoulos-Ioannidis; Panagiotis N Papanikolaou; Evangelia E Ntzani; John P A Ioannidis
Journal:  J Gen Intern Med       Date:  2011-02-01       Impact factor: 5.128

Review 6.  Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.

Authors:  R Simó; A Rodriguez; E Caveda
Journal:  Curr Drug Saf       Date:  2010-07-02

7.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

8.  A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

Authors:  Ronald B Goldberg; David M Kendall; Mark A Deeg; John B Buse; Anthony J Zagar; Jane A Pinaire; Meng H Tan; Mehmood A Khan; Alfonso T Perez; Scott J Jacober
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

9.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

10.  Changes in glitazone use among office-based physicians in the U.S., 2003-2009.

Authors:  Andrew Cohen; Atonu Rabbani; Nilay Shah; G Caleb Alexander
Journal:  Diabetes Care       Date:  2010-01-26       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.